+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

From
From
Gout Therapeutics Global Market Report 2024 - Product Thumbnail Image

Gout Therapeutics Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
From
From
Warm Autoimmune Hemolytic Anemia (WAIHA) - Pipeline Insight, 2020 - Product Thumbnail Image

Warm Autoimmune Hemolytic Anemia (WAIHA) - Pipeline Insight, 2020

  • Clinical Trials
  • September 2020
  • 70 Pages
  • Global
From
Gouty Arthritis (Gout) - Pipeline Review, H2 2020 - Product Thumbnail Image

Gouty Arthritis (Gout) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 139 Pages
  • Global
From
From
Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2020 - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 68 Pages
  • Global
From
Autoimmune Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2024

  • Report
  • April 2024
  • 500 Pages +
  • Global
From
From
From
From
Loading Indicator